Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250
micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of
age over a 12-month treatment period.